Neurodon Corporation is focused on discovering and developing disease-modifying therapies for intractable diseases by addressing endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach utilizes first-in-class modulators to restore calcium levels in cells, enabling the creation of therapeutics for conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and diabetes. Founded in 2019 and based in Crown Point, Indiana, Neurodon has advanced two candidates into IND-enabling studies, with plans to commence clinical trials in 2025. The company has raised over $11 million through various funding sources, including grants and partnerships, and is currently seeking additional funding to support its upcoming clinical studies. Neurodon’s unique platform technology positions it as a leader in addressing diseases linked to ER stress, with no direct competitors targeting the same mechanism of action.
The Indiana CTSI
Grant in 2023
The Indiana CTSI is dedicated to leveraging and strengthening the state’s life sciences community to achieve better health for people in Indiana.Leadership and staff at the Indiana CTSI are working to develop the best processes and resources to enable the efficient translation of scientific discoveries to patient care.Indiana CTSI programs and partnerships are designed to educate, attract and retain top research talent in the state for generations to come.
Indiana University School of Medicine
Grant in 2022
The Indiana University School of Medicine is the largest medical school in the United States. The IU School of Medicine, which is made up of five fundamental science departments and twenty clinical departments, provides superior training for students interested in pursuing a medical degree. The school launched a new medical education curriculum with the Class of 2020 that better represents the modern U.S. health care environment and delivery methods, preparing students to practice medicine in a team-based, multidisciplinary setting.
Indiana University
Grant in 2020
Indiana University, established in 1820 and located in Bloomington, Indiana, is a public research-intensive institution recognized for its commitment to liberal arts, sciences, and professional education. It focuses on creating, disseminating, preserving, and applying knowledge through innovative research, diverse educational programs, and meaningful extracurricular experiences. The university offers a wide range of undergraduate and graduate degrees, emphasizing professional, medical, and technological education while ensuring broad access for students from Indiana and beyond. Indiana University is dedicated to fostering a culturally diverse community and maintaining an environment that supports academic freedom and collegiality. Additionally, it plays a vital role in regional economic development and provides extensive academic and cultural resources to enhance student learning and engagement.
Neurodon Corporation is focused on discovering and developing disease-modifying therapies for intractable diseases by addressing endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach utilizes first-in-class modulators to restore calcium levels in cells, enabling the creation of therapeutics for conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and diabetes. Founded in 2019 and based in Crown Point, Indiana, Neurodon has advanced two candidates into IND-enabling studies, with plans to commence clinical trials in 2025. The company has raised over $11 million through various funding sources, including grants and partnerships, and is currently seeking additional funding to support its upcoming clinical studies. Neurodon’s unique platform technology positions it as a leader in addressing diseases linked to ER stress, with no direct competitors targeting the same mechanism of action.
AgeneBio, Inc. is a neuroscience pharmaceutical company founded in 2008 by Dr. Michela Gallagher, focused on developing therapeutic products for Alzheimer's disease, dementia, and other memory disorders. The company's primary targets include Amnestic Mild Cognitive Impairment (aMCI) and Alzheimer's disease (AD). AgeneBio aims to create innovative therapeutics that prevent neurodegeneration and preserve cognitive function in patients at risk for neurological and psychiatric conditions. By addressing the symptomatic pre-dementia stage of Alzheimer's disease and other related disorders, AgeneBio seeks to provide effective treatments for individuals facing these challenging health issues. The company is headquartered in Indianapolis, Indiana, and engages in global research and development efforts through various partnerships.
Recovery Force
Grant in 2019
Recovery Force Health, LLC, based in Fishers, Indiana, specializes in the development and manufacturing of innovative health care apparel and wearable medical technology. Founded in 2013 by Matthew Wyatt, the company emerged from a personal experience where Wyatt sought to improve patient care following surgical procedures. Recovery Force offers a range of products, including sleeves and shoes, designed for healthcare professionals, patients, and athletes. Central to their offerings is the MORPH system, which utilizes S.M.A.R.T. technology and nitinol to provide rhythmic, sequential compression that enhances blood flow to targeted areas of the body. Their non-pneumatic platform aims to reduce post-operative pain and swelling, expedite wound healing, treat chronic lymphedema, and alleviate joint pain and muscle soreness. Recovery Force is committed to integrating data-driven solutions throughout the continuum of care, from hospital settings to home recovery.
Novosteo Inc., founded in 2017 and located in West Lafayette, Indiana, focuses on developing and manufacturing innovative drugs aimed at treating bone injuries and diseases. The company addresses significant health issues related to bone fractures, including morbidity, mortality, and reduced mobility and productivity. Its scientific co-founders from Purdue University have pioneered a proprietary chemistry approach that targets bone regeneration. Novosteo's drug discovery platform features a range of fracture-targeted therapeutics designed to deliver healing agents directly to fracture sites, enhancing the healing process and alleviating the debilitating effects associated with bone injuries. Through its novel biologics, Novosteo aims to improve patient outcomes and quality of life.
Neurodon Corporation is focused on discovering and developing disease-modifying therapies for intractable diseases by addressing endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach utilizes first-in-class modulators to restore calcium levels in cells, enabling the creation of therapeutics for conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and diabetes. Founded in 2019 and based in Crown Point, Indiana, Neurodon has advanced two candidates into IND-enabling studies, with plans to commence clinical trials in 2025. The company has raised over $11 million through various funding sources, including grants and partnerships, and is currently seeking additional funding to support its upcoming clinical studies. Neurodon’s unique platform technology positions it as a leader in addressing diseases linked to ER stress, with no direct competitors targeting the same mechanism of action.
The Indiana CTSI
Grant in 2018
The Indiana CTSI is dedicated to leveraging and strengthening the state’s life sciences community to achieve better health for people in Indiana.Leadership and staff at the Indiana CTSI are working to develop the best processes and resources to enable the efficient translation of scientific discoveries to patient care.Indiana CTSI programs and partnerships are designed to educate, attract and retain top research talent in the state for generations to come.
Fast Biomedical
Grant in 2017
Fast Biomedical is a clinical-stage medical technology company based in Indiana, dedicated to the development and commercialization of an innovative technology for quantifying critical health parameters that have historically been difficult to measure. The company's primary focus is on assessing blood volume and kidney function in a clinically viable manner. Fast Biomedical's technology utilizes a fluorescent compound to enhance the detection of kidney infections, allowing for faster identification of acute kidney failure compared to traditional lab tests. By injecting markers into a patient's bloodstream that fluoresce when analyzed with their device, physicians can more effectively monitor kidney health and improve patient outcomes.
Indiana University
Grant in 2017
Indiana University, established in 1820 and located in Bloomington, Indiana, is a public research-intensive institution recognized for its commitment to liberal arts, sciences, and professional education. It focuses on creating, disseminating, preserving, and applying knowledge through innovative research, diverse educational programs, and meaningful extracurricular experiences. The university offers a wide range of undergraduate and graduate degrees, emphasizing professional, medical, and technological education while ensuring broad access for students from Indiana and beyond. Indiana University is dedicated to fostering a culturally diverse community and maintaining an environment that supports academic freedom and collegiality. Additionally, it plays a vital role in regional economic development and provides extensive academic and cultural resources to enhance student learning and engagement.
KinaSense LLC is a biotechnology company based in West Lafayette, Indiana, focused on developing products for the pre-clinical and clinical phases of cancer drug discovery. Founded in 2013, the company specializes in cancer diagnostic solutions, particularly in the area of tyrosine kinase inhibitors (TKIs), which are widely used to treat various types of cancer. KinaSense is dedicated to creating technologies that enhance the predictive power of current diagnostic tools, aiming to determine which patients are most likely to benefit from specific TKIs. Their offerings include assays and cell-based kits designed to measure the efficacy and selectivity of TKIs, ultimately enabling a more personalized approach to cancer treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.